SCHEMBL21358331

SCHEMBL21358331

COCCCOc1cc(O)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
L3MBTL1 Q9Y468 5/20 0.45
MAPK1 P28482 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
ALOX12 P18054 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KDM4E B2RXH2 7/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22964315 0.91 L3MBTL1 (0.50) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL14214407 0.84 LTA4H (0.49) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL16096116 0.82 BACE1 (0.46) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL17534208 0.82 CSNK2A1 (0.47) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL9699832 0.81 NR5A1 (0.54) MAPTMEN1KMT2ACYP3A4HTT
SCHEMBL89077 0.81 L3MBTL1 (0.68) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL3915123 0.81 CHRNB4 (0.50) MAPTL3MBTL1HPGDNPC1RAB9A
SCHEMBL21477276 0.80 ALDH1A1 (0.49) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL8285816 0.80 ALDH1A1 (0.43) MAPTL3MBTL1MAPK1ALDH1A1HPGD
SCHEMBL22714464 0.79 L3MBTL1 (0.45) MAPTL3MBTL1MAPK1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2023-07-18 US disclosed
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2023-07-18 US disclosed
US-20210017186-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-01-21 US disclosed
US-20210017186-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-01-21 US disclosed
WO-2019177937-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702427-B2 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same HAVCR2, HPD, CYP24A1 MAPT 551/4885L3MBTL1 3190/4885MAPK1 2247/4885
US-20210017186-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HPD, CYP24A1 MAPT 551/4885L3MBTL1 3190/4885MAPK1 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.